TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17593136

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Functional Dyspepsia (FD)
Number of subjects: 16
Study: 16198653

Group type: EXPERIMENTAL
Intervention: OATP 1B1 *1b/*1b genotype
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OATP 1B1 *1a/*1a or *1a/*1b genotype
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OATP 1B1 *1a/*15 or *1b/*15 genotype
Number of subjects: 24
Study: 12822088

Group type: EXPERIMENTAL
Intervention: Surgery (resection and drainage procedures)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Endotherapy (sphincterotomy, stenting, and/or stone removal)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Endotherapy
Number of subjects: 72
Study: 11783209

Group type: EXPERIMENTAL
Intervention: Quick-acting Kuijie powder (QAKJP) retention enema
Number of subjects: 234

Group type: COMPARATOR
Intervention: Sulfasalazine orally (control)
Number of subjects: 234
Study: 7791603

Group type: EXPERIMENTAL
Intervention: Cover stories involving different pairs of element sets (e.g., objects and people)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cover stories involving similar sets of people (e.g., doctors and doctors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfer of problem-solving skills
Number of subjects: 0
Study: 1787651

Group type: EXPERIMENTAL
Intervention: 4% branched-chain amino acid (BCAA) solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 6989682

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/amiloride (Moduretic)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 25
Study: 31398726

Group type: EXPERIMENTAL
Intervention: Technology-based intervention (LanguageLinks: Syntax Assessment and Intervention®; Laureate Learning Systems, Inc., 2013)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study: 31564503

Group type: EXPERIMENTAL
Intervention: MID‐O2 (midazolam 1 mg kg‐1 IM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SAL‐N2O (saline IM and isoflurane with 50% nitrous oxide)
Number of subjects: 9

Group type: COMPARATOR
Intervention: SAL‐O2 (saline IM and isoflurane‐oxygen)
Number of subjects: 9
Study: 28034985

Group type: EXPERIMENTAL
Intervention: Submaximal, isometric exercise for three minutes
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Positive family environments
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Negative and chronic pain-present family environments
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Situational catastrophizing and negative mood state
Number of subjects: 58
Study: 25879193

Group type: EXPERIMENTAL
Intervention: Sustained Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 23617535

Group type: EXPERIMENTAL
Intervention: Pterygium surgery using conjunctival autograft technique
Number of subjects: 21
Study: 21318929

Group type: EXPERIMENTAL
Intervention: Positive Action programme
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 510
Study: 19947365

Group type: EXPERIMENTAL
Intervention: Combined use of the virus vaccine and chemotherapy (group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Therapy with the vaccine alone (group B)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Chemotherapy regimen identical with that used in group A (group C)
Number of subjects: 84
Study: 17456483

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid for 4 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 15689099

Group type: EXPERIMENTAL
Intervention: Four questions on knowledge and beliefs about smoking, standardized verbal advice against smoking, and a leaflet
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 387
Study: 12953348

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg coadministered with digoxin on Day 7
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg coadministered with digoxin on Days 8 to 11
Number of subjects: 12
Study: 9854128

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal laparoscopic hernia repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open tension‐free hernia repair
Number of subjects: 0
Study: 8682031

Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg for paroxysmal supraventricular tachycardia
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Flecainide 200 mg for paroxysmal atrial fibrillation
Number of subjects: 335

Group type: COMPARATOR
Intervention: Propafenone 450 mg for paroxysmal supraventricular tachycardia
Number of subjects: 335

Group type: COMPARATOR
Intervention: Propafenone 450 mg for paroxysmal atrial fibrillation
Number of subjects: 335
Study: 2211279

Group type: EXPERIMENTAL
Intervention: Milk coupon incentive
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Gift for teenage mother incentive
Number of subjects: 534

Group type: COMPARATOR
Intervention: No incentive (control)
Number of subjects: 534
Study: 508609

Group type: EXPERIMENTAL
Intervention: Decrease skin conductance training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Increase skin conductance training
Number of subjects: 33
Study: 31584063

Group type: EXPERIMENTAL
Intervention: 1% fat milk
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 31% fat cheddar cheese
Number of subjects: 55

Group type: COMPARATOR
Intervention: No dairy (control diet)
Number of subjects: 55
Study: 30680980

Group type: EXPERIMENTAL
Intervention: Alkalinized 2% lidocaine (group L)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Air (group A)
Number of subjects: 90
Study: 27856630

Group type: EXPERIMENTAL
Intervention: 18F‐fluciclovine PET/CT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 26404367

Group type: EXPERIMENTAL
Intervention: Low Satiety Phenotype (LSP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High Satiety Phenotype (HSP)
Number of subjects: 30
Study: 23460036

Group type: EXPERIMENTAL
Intervention: Polysensitisation (>2 sensitisations)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Positive IgE test for one or more allergens
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Age group 9-13 years
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Polysensitised children
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Non-sensitised children
Number of subjects: 784
Study: 20628752

Group type: EXPERIMENTAL
Intervention: Tissue welding tonsillectomy (TW-TE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monopolar electrocautery tonsillectomy (monopolar-TE)
Number of subjects: 60
Study: 19687522

Group type: EXPERIMENTAL
Intervention: Care from a nurse specialised in diabetes (NSD)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Care from an internist (Control)
Number of subjects: 84
Study: 17336817

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (mean of 1.66 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (holding the infant swaddled in blankets)
Number of subjects: 20
Study: 15383189

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler therapy (160/4.5 microg, 2 inhalations once daily)
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler therapy
Number of subjects: 1890

Group type: COMPARATOR
Intervention: Budesonide (160 microg, 2 inhalations twice daily) plus terbutaline 0.4 mg as needed
Number of subjects: 1890
Study: 11480224

Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg intravenously (gr. 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diazepam 30 mg orally (gr. 2)
Number of subjects: 16
Study: 9737058

Group type: EXPERIMENTAL
Intervention: Angry faces paired with shock
Number of subjects: 60

Group type: COMPARATOR
Intervention: Angry faces paired with siren or nothing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Women faces
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Men faces
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Initial expectancies
Number of subjects: 60
Study: 31656294

Group type: EXPERIMENTAL
Intervention: Single-injection intraarticular anesthesia
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuous epidural anesthesia
Number of subjects: 48
Study: 28652065

Group type: EXPERIMENTAL
Intervention: tDCS‐SM group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 25517501

Group type: EXPERIMENTAL
Intervention: Bundle therapy (Tracheostomy followed by ventilator-Assisted breathing with reverse trendelenburg position, early goal-directed hemodynamic support, enteral nutrition by nasointestinal tube, effective antibiotic usage and large doses of expectorants)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bundle therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 49
Study: 23558793

Group type: EXPERIMENTAL
Intervention: Loss of extension test (LOE test) in ACL-insufficient group
Number of subjects: 196

Group type: COMPARATOR
Intervention: Normal maximum passive extension (MPE) in healthy population
Number of subjects: 196

Group type: COMPARATOR
Intervention: Overall average side-to-side difference in MPE of the injured group
Number of subjects: 196
Study: 19546268

Group type: EXPERIMENTAL
Intervention: Amethocaine
Number of subjects: 2837

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 2837
Study: 17897912

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) treatment
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no PE treatment)
Number of subjects: 220
Study: 15030621

Group type: EXPERIMENTAL
Intervention: Accurate procedures with unbiased leader
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accurate procedures with biased leader
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biased leader
Number of subjects: 0
Study: 11929022

Group type: EXPERIMENTAL
Intervention: Automated algorithm based on artificial neural network (ANN) for joint location identification
Number of subjects: 110

Group type: COMPARATOR
Intervention: Manual tracing by a trained radiologist
Number of subjects: 110
Study: 9797798

Group type: EXPERIMENTAL
Intervention: Single subcutaneous doses of epoetin alfa (300, 450, 600, 900, 1200, 1350, 1800, and 2400 IU/kg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Multiple subcutaneous doses of epoetin alfa (150 IU/kg 3 times a week for 4 weeks)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Multiple subcutaneous doses of epoetin alfa (600 IU/kg once per week for 4 weeks)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Single-dose regimens of epoetin alfa
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation
Number of subjects: 2
Study: 7635124

Group type: EXPERIMENTAL
Intervention: Headlight‐using motorcyclists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated exposure to headlight‐using motorcyclists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60% of motorcyclists using their headlight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory conditions
Number of subjects: 0
Study: 2696417

Group type: EXPERIMENTAL
Intervention: Nyström nails
Number of subjects: 137

Group type: COMPARATOR
Intervention: Scand screws
Number of subjects: 137
Study: 636501

Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 163

Group type: COMPARATOR
Intervention: No antimicrobial chemotherapy
Number of subjects: 163
Study: 31650916

Group type: EXPERIMENTAL
Intervention: Mini-open carpal tunnel release
Number of subjects: 13

Group type: COMPARATOR
Intervention: Uni-portal endoscopic carpal tunnel release
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 13
Study: 28591523

Group type: EXPERIMENTAL
Intervention: Immediate completion lymph-node dissection
Number of subjects: 1934

Group type: COMPARATOR
Intervention: Nodal observation with ultrasonography
Number of subjects: 1934
Study: 26860020

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 48
Study: 23248028

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of mycophenolate mofetil (MMF) and pulse dexamethasone (DEX)
Number of subjects: 0
Study: 21300571

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study: 19076110

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/ml, 1 ml/kg with DEX 1 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg/ml, 1 ml/kg
Number of subjects: 60
Study: 17574137

Group type: EXPERIMENTAL
Intervention: Linear tutorial layout
Number of subjects: 139

Group type: COMPARATOR
Intervention: Web-style tutorial layout
Number of subjects: 139
Study: 15051744

Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 125 mg every 12 hours for 3 days, then every 24 hours for 5 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg coadministered on Day 8
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11605290

Group type: EXPERIMENTAL
Intervention: Extracorporal shock wave therapy (ESWT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: X‐ray stimulation radiotherapy
Number of subjects: 30
Study: 9738804

Group type: EXPERIMENTAL
Intervention: CT + RT
Number of subjects: 46

Group type: COMPARATOR
Intervention: surgery and RT
Number of subjects: 46
Study: 8046475

Group type: COMPARATOR
Intervention: Standard dose of dipyridamole (0.14 mg/kg/min for 4 min, total 0.56 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High dose of dipyridamole (0.14 mg/kg/min for 6 min, total 0.84 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both doses of dipyridamole
Number of subjects: 24
Study: 2927858

Group type: EXPERIMENTAL
Intervention: Bilateral manual breast massage
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Unilateral pump stimulation
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Heating pad stimulation
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 31115462

Group type: EXPERIMENTAL
Intervention: Dietary fulvic acid supplementation (0.6 g kg‐1)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Dietary fulvic acid supplementation (1 g kg‐1)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Dietary fulvic acid supplementation (0.2 g kg‐1)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (no fulvic acid supplementation)
Number of subjects: 720
Study: 28291866

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Number of subjects: 15281

Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 15281
Study: 26397109

Group type: EXPERIMENTAL
Intervention: Standard-length adaptive Cogmed WM training (CWMT; 45‐min/session)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Shortened-length adaptive version of CWMT (15 min/session)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No training group (waitlist-control group)
Number of subjects: 97
Study: 23412113

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge (4 mg deliverable)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 30
Study: 21466258

Group type: EXPERIMENTAL
Intervention: Probiotic ice-cream containing Bifidobacterium lactis Bb12 and Lactobacillus acidophilus La5
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control ice-cream (placebo)
Number of subjects: 40
Study: 19884613

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus nicotine lozenge
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Bupropion plus nicotine lozenge
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1504
Study: 17704968

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection for colorectal cancer
Number of subjects: 818

Group type: COMPARATOR
Intervention: Open resection for colorectal cancer
Number of subjects: 818
Study: 15182772

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11777720

Group type: EXPERIMENTAL
Intervention: 5.5 mm scleral tunnel with PMMA IOL implantation
Number of subjects: 81

Group type: COMPARATOR
Intervention: 3.5 mm clear corneal incision (CCI) with silicone foldable IOL implantation
Number of subjects: 81

Group type: COMPARATOR
Intervention: 5.5 mm sutured CCI with PMMA IOL implantation
Number of subjects: 81
Study: 9651636

Group type: EXPERIMENTAL
Intervention: Por La Vida (PLV) cancer screening intervention group
Number of subjects: 504

Group type: COMPARATOR
Intervention: Community Living Skills control group
Number of subjects: 504
Study: 7905143

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 58600
Study: 2671414

Group type: EXPERIMENTAL
Intervention: Papaverine (40 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Papaverine (20 mg) and Phentolamine (0.5 mg)
Number of subjects: 40
Study: 797539

Group type: EXPERIMENTAL
Intervention: 10 mg clotrimazole troche, ten times a day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg clotrimazole troche, ten times a day
Number of subjects: 12
Study: 28525632

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 or 450 mg/day, twice daily)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 27286894

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant) only
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant) with other RVO treatment
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant) with ≥2 DEX implants
Number of subjects: 375
Study: 24674676

Group type: EXPERIMENTAL
Intervention: Renagel (Genzyme manufacturer)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Generic equivalent (EMS manufacturer)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both sevelamer tablet forms
Number of subjects: 28
Study: 22809563

Group type: EXPERIMENTAL
Intervention: Intraluminal-left anterior descending shunt
Number of subjects: 38

Group type: COMPARATOR
Intervention: External tournique occlusion
Number of subjects: 38
Study: 20430577

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined ETN+MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: German etanercept registry
Number of subjects: 0
Study: 17591482

Group type: COMPARATOR
Intervention: Standard verbal report (VR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Standard verbal report followed by a computer-generated endoscopy report (VR+WR)
Number of subjects: 80
Study: 15649160

Group type: EXPERIMENTAL
Intervention: Epidural morphine 11.2 microg.kg(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural morphine 15 microg.kg(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural morphine 20 microg.kg(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (11.2, 15, 20 microg.kg(‐1))
Number of subjects: 45
Study: 12107208

Group type: EXPERIMENTAL
Intervention: 2.5 microg rhGH/kg body weight per day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3.3 microg rhGH/kg body weight per day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 10073860

Group type: EXPERIMENTAL
Intervention: Active pacing mode
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inactive pacing mode
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both active and inactive pacing modes
Number of subjects: 10
Study: 7720945

Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg at 8:00 and 0.75 mg at 10:00 and 12:00 A.M.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1974484

Group type: EXPERIMENTAL
Intervention: Arginine (ARG) 0.5 g/kg infused i.v. over 30 min with GHRH 1 microgram/kg i.v.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Arginine (ARG) 0.5 g/kg infused i.v. with Pyridostigmine (PD) 60 mg orally
Number of subjects: 15

Group type: COMPARATOR
Intervention: GHRH 1 microgram/kg i.v. alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined PD and GHRH administration
Number of subjects: 15
Study: 7237220

Group type: EXPERIMENTAL
Intervention: Low dose droperidol (0.005 mg x kg‐1)
Number of subjects: 200
Study: 31810943

Group type: EXPERIMENTAL
Intervention: Placement of a self‐expandable metal stent (Group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Primary tumor resection (Group 2)
Number of subjects: 46
Study: 28447625

Group type: EXPERIMENTAL
Intervention: Dietary supplements (combination pill)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 26219694

Group type: EXPERIMENTAL
Intervention: BCG + OPV0
Number of subjects: 7012

Group type: COMPARATOR
Intervention: BCG only
Number of subjects: 7012

Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (boys)
Number of subjects: 7012

Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (girls)
Number of subjects: 7012

Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (enrolled within first 2 days)
Number of subjects: 7012

Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (before OPV campaigns)
Number of subjects: 7012
Study: 24419064

Group type: EXPERIMENTAL
Intervention: Maraviroc-containing regimens
Number of subjects: 938
Study: 21777972

Group type: EXPERIMENTAL
Intervention: HSCT (200 mg/kg intravenous cyclophosphamide, 6.5 mg/kg intravenous rabbit antithymocyte globulin)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cyclophosphamide (1.0 g/m² intravenous once per month for 6 months)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HSCT (after switching from cyclophosphamide)
Number of subjects: 19
Study: 19302017

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unboosted atazanavir
Number of subjects: 0